It's important to note that Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved for chronic weight management, while Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes management, though sometimes used off-label for weight loss
We thank grants HL143037 (to J.S.), R35GM128641, and R03TR003306 (to C.Z.) from the National Institutes of Health, USA
Although rare, these severe side effects can occur, and medical professionals can effectively manage them
GLP-1s meaningfully reduce hunger and binge-eating frequency for many people, and for the right patient, that shift can be genuinely transformative
Constipation may become more uncomfortable when a person is eating less, drinking less water, or consuming insufficient fiber
For anyone in Canada doing this properly, thats where Id start